|
86 Companies |
|
137 Products |
|
137 Products |
|
85 Mechanisms of Action |
|
4 Trials |
|
2019 News |
|
| «12...1314151617181920212223...3940» |
- ||| balipodect (TAK-063) / Takeda
Trial completion, Enrollment change, Trial primary completion date: Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants (clinicaltrials.gov) - Aug 15, 2014
P1, N=77, Completed, Sponsor: Takeda
Recruiting --> Completed | N=60 --> 77 | Trial primary completion date: Feb 2014 --> Jun 2014
- Trial primary completion date: Aftercare in the Community Health Center (clinicaltrials.gov) - Aug 12, 2014
P=N/A, N=140, Recruiting, Sponsor: Norwegian University of Science and Technology
Recruiting --> Completed | N=60 --> 77 | Trial primary completion date: Feb 2014 --> Jun 2014 Trial primary completion date: May 2014 --> Dec 2015
- Enrollment open, Enrollment change: Computerised Interventions for Thinking and Anxiety in Delusions (CITADEL) Trial (clinicaltrials.gov) - Aug 12, 2014
P=N/A, N=46, Recruiting, Sponsor: King's College London
Trial primary completion date: May 2014 --> Dec 2015 Not yet recruiting --> Recruiting | N=72 --> 46
- RO5545965 / Roche
Enrollment closed, Enrollment change: A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone (clinicaltrials.gov) - Aug 12, 2014
P1, N=32, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting | N=72 --> 46 Recruiting --> Active, not recruiting | N=48 --> 32
- || Enrollment closed, Trial primary completion date: An Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia (clinicaltrials.gov) - Aug 12, 2014
P=N/A, N=1433, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=48 --> 32 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Dec 2015
- Enrollment closed: Reducing Internalized Stigma in People With Serious Mental Illness (clinicaltrials.gov) - Aug 12, 2014
P2, N=276, Active, not recruiting, Sponsor: Department of Veterans Affairs
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Dec 2015 Recruiting --> Active, not recruiting
- Trial completion: Clinical Symptoms of Schizophrenia and Physical Exercise (clinicaltrials.gov) - Aug 12, 2014
P=N/A, N=47, Completed, Sponsor: Federal University of S
Recruiting --> Active, not recruiting Recruiting --> Completed
- Clinical: APUS e-Cigs: Electronic Cigarettes in Smokers With Mental Illness (clinicaltrials.gov) - Aug 8, 2014
P=N/A, N=50, Not yet recruiting, Sponsor: King's College London
- Enrollment closed: SAFARI: Return to Work: Promoting Health and Productivity in Workers With Common Mental Disorders (clinicaltrials.gov) - Aug 8, 2014
P=N/A, N=320, Active, not recruiting, Sponsor: Karolinska Institutet
Recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment change: Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia (clinicaltrials.gov) - Aug 7, 2014
P4, N=38, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting N=50 --> 38
- ||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Enrollment change, Trial primary completion date: A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial (clinicaltrials.gov) - Aug 6, 2014
P3, N=2363, Recruiting, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
N=50 --> 38 N=1785 --> 2363 | Trial primary completion date: Nov 2015 --> May 2016
- Trial primary completion date: SGE-PsyScan: Supporting Primary Care in Diagnosis and Choice of Treatment for Patients With Psychosocial Symptoms: SGEPsyScan. (clinicaltrials.gov) - Aug 5, 2014
P=N/A, N=648, Recruiting, Sponsor: Maastricht University Medical Center
N=1785 --> 2363 | Trial primary completion date: Nov 2015 --> May 2016 Trial primary completion date: May 2015 --> Sep 2015
- Enrollment open: Testing Effect and Schizophrenia (clinicaltrials.gov) - Aug 5, 2014
P=N/A, N=50, Recruiting, Sponsor: University Hospital, Strasbourg, France
Trial primary completion date: May 2015 --> Sep 2015 Not yet recruiting --> Recruiting
- methamphetamine / Generic mfg.
Trial completion: Development of a Family-Based Treatment for Adolescent Methamphetamine Use (clinicaltrials.gov) - Aug 5, 2014
P1, N=60, Completed, Sponsor: Oregon Research Institute
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- risperidone / Generic mfg., paliperidone extended release / Generic mfg.
Trial primary completion date: A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia (clinicaltrials.gov) - Aug 1, 2014
P4, N=50, Recruiting, Sponsor: Johnson & Johnson Taiwan Ltd
Active, not recruiting --> Completed Trial primary completion date: Jun 2014 --> Jun 2015
- olanzapine / Generic mfg.
Enrollment change: CRASOD: Cardio Risk of Acute Schizophrenia Olanzapine Duke (clinicaltrials.gov) - Aug 1, 2014
P4, N=0, Withdrawn, Sponsor: Duke University
Trial primary completion date: Jun 2014 --> Jun 2015 N=160 --> 0
- | SKL-15508 / SK Bio
New P1/2 trial: A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia (clinicaltrials.gov) - Aug 1, 2014
P1/2, N=48, Not yet recruiting, Sponsor: SK Life Science
- ||||||| bitopertin (DISC-1459) / Disc Medicine
Trial completion: A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309) (clinicaltrials.gov) - Aug 1, 2014
P3, N=624, Completed, Sponsor: Hoffmann-La Roche
N=160 --> 0 Active, not recruiting --> Completed
- |||||||||| Perseris (risperidone sustained-release 1-month depot) / Indivior, Reckitt Benckiser, HLS Therap
Clinical: Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia (clinicaltrials.gov) - Jul 30, 2014
P3, N=500, Recruiting, Sponsor: Reckitt Benckiser Pharmaceuticals Inc.
- ||| Lu AF35700 / Lundbeck, Jiangsu NHWA Pharma
New P1 trial: Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia (clinicaltrials.gov) - Jul 30, 2014
P1, N=90, Recruiting, Sponsor: H. Lundbeck A/S
- ||| Lu AF11167 / Lundbeck
New P1 trial: Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia (clinicaltrials.gov) - Jul 28, 2014
P1, N=72, Recruiting, Sponsor: H. Lundbeck A/S
- | Biomarker, Phase classification: Metabolic Signatures and Biomarkers in Schizophrenia (clinicaltrials.gov) - Jul 27, 2014
P1, N=71, Completed, Sponsor: Duke University
Active, not recruiting --> Completed Phase classification: P4 --> P1
- Enrollment change: Predictors of Response to Cognitive Remediation in Schizophrenia (clinicaltrials.gov) - Jul 24, 2014
P=N/A, N=103, Completed, Sponsor: Department of Veterans Affairs
Phase classification: P4 --> P1 N=75 --> 103
- Clinical: Self Directed Positive Parenting Program (Triple P) for Psychosis: A Clinical Case Series (clinicaltrials.gov) - Jul 24, 2014
P=N/A, N=6, Recruiting, Sponsor: University of Manchester
- Enrollment open: Internal Monitoring of Eye Movement in Schizophrenia (clinicaltrials.gov) - Jul 24, 2014
P=N/A, N=25, Recruiting, Sponsor: National Eye Institute (NEI)
N=75 --> 103 Not yet recruiting --> Recruiting
- |||||||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
New P3 trial: Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress (clinicaltrials.gov) - Jul 23, 2014
P3, N=900, Recruiting, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
- | New P2 trial: Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia (clinicaltrials.gov) - Jul 23, 2014
P2, N=80, Not yet recruiting, Sponsor: New York University School of Medicine
- Trial completion: Predictors of Response to Cognitive Remediation in Schizophrenia (clinicaltrials.gov) - Jul 23, 2014
P=N/A, N=75, Completed, Sponsor: Department of Veterans Affairs
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
New P3 trial, Monotherapy: Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity (clinicaltrials.gov) - Jul 21, 2014
P3, N=30, Not yet recruiting, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
- | Enrollment closed, Enrollment change: HOSPIPalm: A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital Setting (clinicaltrials.gov) - Jul 18, 2014
P4, N=13, Active, not recruiting, Sponsor: Janssen-Cilag International NV
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=450 --> 13
- Trial initiation date, Trial primary completion date: Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders (clinicaltrials.gov) - Jul 17, 2014
P2, N=2, Enrolling by invitation, Sponsor: Mclean Hospital
Recruiting --> Active, not recruiting | N=450 --> 13 Initiation date: Sep 2012 --> Dec 2012 | Trial primary completion date: Aug 2014 --> Aug 2015
- Clinical: Computerized Cognitive-Behavioral Therapy for Auditory Hallucinations (clinicaltrials.gov) - Jul 17, 2014
P=N/A, N=40, Active, not recruiting, Sponsor: Boston University
- ||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Clinical: Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo (clinicaltrials.gov) - Jul 17, 2014
P=N/A, N=520, Enrolling by invitation, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
- Clinical: A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia (clinicaltrials.gov) - Jul 17, 2014
P=N/A, N=550, Completed, Sponsor: Beijing Hui-Long-Guan Hospital
- Risperdal Consta (risperidone depot formulation) / J&J
Trial completion, Trial primary completion date: PROACTIVE: Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy (clinicaltrials.gov) - Jul 15, 2014
P4, N=357, Completed, Sponsor: North Shore Long Island Jewish Health System
Initiation date: Sep 2012 --> Dec 2012 | Trial primary completion date: Aug 2014 --> Aug 2015 Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> Jan 2011
- Enrollment closed: The Family Cognitive Adaptation Training Manual: A Test of Effectiveness (clinicaltrials.gov) - Jul 14, 2014
P=N/A, N=40, Active, not recruiting, Sponsor: Centre for Addiction and Mental Health
Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> Jan 2011 Recruiting --> Active, not recruiting
- Clinical: The Effectiveness of the Meta-cognitive Training Among Patients With Chronic Schizophrenia (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=50, Completed, Sponsor: Medical University of Warsaw
- | Rykindo (risperidone extended release microspheres) / Luye Group
New P1 trial: An Randomized Open-Label PK Study of LY03004 Compared to Risperdal (clinicaltrials.gov) - Jul 12, 2014
P1, N=16, Not yet recruiting, Sponsor: Luye Pharma Group Ltd.
- Trial completion, Enrollment change: Study of Mindfulness-based Group Treatment in Patients With Depression and Anxiety (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=215, Completed, Sponsor: Lund University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=300 --> 215
- Rykindo (risperidone extended release microspheres) / Luye Group
Trial primary completion date: LY03004SAD: Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov) - Jul 10, 2014
P1, N=32, Completed, Sponsor: Luye Pharma Group Ltd.
Active, not recruiting --> Completed | N=300 --> 215 Trial primary completion date: Sep 2014 --> Jun 2014
- minocycline / Generic mfg.
Trial primary completion date: MINOS: Minocycline for Schizophrenia (clinicaltrials.gov) - Jul 10, 2014
P4, N=150, Recruiting, Sponsor: Addis Ababa University
Trial primary completion date: Sep 2014 --> Jun 2014 Trial primary completion date: Mar 2014 --> Jun 2015
- Enrollment open: RCTEDSS: Randomized Controlled Trial (RCT) of a Motivational Decision Support System (clinicaltrials.gov) - Jul 10, 2014
P=N/A, N=174, Recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Trial primary completion date: Mar 2014 --> Jun 2015 Not yet recruiting --> Recruiting
- minocycline / Generic mfg.
Enrollment open, Trial primary completion date: MINOS: Minocycline for Schizophrenia (clinicaltrials.gov) - Jul 10, 2014
P4, N=150, Recruiting, Sponsor: Addis Ababa University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2014 --> Jun 2015
- | Rykindo (risperidone extended release microspheres) / Luye Group
Trial completion, Trial primary completion date: LY03004SAD: Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov) - Jul 10, 2014
P1, N=32, Completed, Sponsor: Luye Pharma Group Ltd.
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2014 --> Jun 2015 Recruiting --> Completed | Trial primary completion date: Sep 2014 --> Jun 2014
- Trial primary completion date: Cognitive Remediation of Schizophrenia in a Community Mental Health Setting (clinicaltrials.gov) - Jul 8, 2014
P=N/A, N=120, Recruiting, Sponsor: University of California, San Francisco
Recruiting --> Completed | Trial primary completion date: Sep 2014 --> Jun 2014 Trial primary completion date: Sep 2014 --> May 2015
- Trial primary completion date: Illness Management and Recovery (IMR) in Danish Community Mental Health Centres (clinicaltrials.gov) - Jul 8, 2014
P=N/A, N=200, Active, not recruiting, Sponsor: Mental Health Centre Copenhagen
Trial primary completion date: Sep 2014 --> May 2015 Trial primary completion date: Dec 2012 --> Dec 2014
- Trial primary completion date: Effectiveness of Neuroadaptive Cognitive Training in Adolescents at Risk for Psychosis (clinicaltrials.gov) - Jul 8, 2014
P1/2, N=100, Recruiting, Sponsor: University of California, San Francisco
Trial primary completion date: Dec 2012 --> Dec 2014 Trial primary completion date: Mar 2014 --> Mar 2015
- ulotaront (SEP-363856) / Otsuka, PsychoGenics
Enrollment change: Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia (clinicaltrials.gov) - Jul 8, 2014
P1, N=48, Completed, Sponsor: Sunovion
Trial primary completion date: Mar 2014 --> Mar 2015 N=60 --> 48
- ulotaront (SEP-363856) / Otsuka, PsychoGenics
Enrollment change: A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia (clinicaltrials.gov) - Jul 8, 2014
P1, N=48, Completed, Sponsor: Sunovion
N=60 --> 48 N=60 --> 48
- Clinical: SPA: A System for Preference Assessment in Mental Health (clinicaltrials.gov) - Jul 8, 2014
P=N/A, N=95, Not yet recruiting, Sponsor: University of California, Los Angeles